Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Depreciation and Depletion (2022 - 2024)

Orchestra BioMed Holdings (OBIO) has disclosed Depreciation and Depletion for 3 consecutive years, with $76000.0 as the latest value for Q3 2024.

  • On a quarterly basis, Depreciation and Depletion rose 7.04% to $76000.0 in Q3 2024 year-over-year; TTM through Sep 2024 was $297000.0, a 4.58% increase, with the full-year FY2023 number at $287000.0, up 29.28% from a year prior.
  • Depreciation and Depletion was $76000.0 for Q3 2024 at Orchestra BioMed Holdings, up from $74000.0 in the prior quarter.
  • In the past five years, Depreciation and Depletion ranged from a high of $76000.0 in Q3 2024 to a low of $48000.0 in Q1 2022.
  • A 3-year average of $66636.4 and a median of $71000.0 in 2023 define the central range for Depreciation and Depletion.
  • Peak YoY movement for Depreciation and Depletion: surged 47.92% in 2023, then increased 2.78% in 2024.
  • Orchestra BioMed Holdings' Depreciation and Depletion stood at $70000.0 in 2022, then grew by 4.29% to $73000.0 in 2023, then rose by 4.11% to $76000.0 in 2024.
  • Per Business Quant, the three most recent readings for OBIO's Depreciation and Depletion are $76000.0 (Q3 2024), $74000.0 (Q2 2024), and $74000.0 (Q1 2024).